Collegium Pharmaceutical (NASDAQ:COLL) Lowered to Buy Rating by Wall Street Zen

Wall Street Zen downgraded shares of Collegium Pharmaceutical (NASDAQ:COLL) from a strong-buy rating to a buy rating in a research report report published on Saturday.

Several other research analysts have also weighed in on COLL. Truist Financial set a $58.00 price objective on shares of Collegium Pharmaceutical in a research note on Tuesday, February 10th. Barclays decreased their target price on shares of Collegium Pharmaceutical from $58.00 to $56.00 and set an “overweight” rating for the company in a research note on Friday, January 9th. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price target (up from $46.00) on shares of Collegium Pharmaceutical in a research note on Friday, January 9th. Zacks Research lowered Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. Finally, Needham & Company LLC lowered their target price on Collegium Pharmaceutical from $56.00 to $54.00 and set a “buy” rating on the stock in a research note on Thursday. Five research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $53.00.

Collegium Pharmaceutical Stock Down 5.8%

NASDAQ:COLL opened at $41.67 on Friday. The firm has a market capitalization of $1.32 billion, a price-to-earnings ratio of 24.37 and a beta of 0.64. Collegium Pharmaceutical has a 1-year low of $23.23 and a 1-year high of $50.79. The company has a current ratio of 1.36, a quick ratio of 1.27 and a debt-to-equity ratio of 2.71. The business’s fifty day moving average price is $46.50 and its 200 day moving average price is $42.06.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Thursday, February 26th. The specialty pharmaceutical company reported $2.04 EPS for the quarter, missing analysts’ consensus estimates of $2.20 by ($0.16). Collegium Pharmaceutical had a return on equity of 104.09% and a net margin of 8.05%.The business had revenue of $205.45 million for the quarter, compared to analyst estimates of $206.36 million. During the same quarter in the previous year, the business posted $1.77 earnings per share. The company’s revenue was up 12.9% compared to the same quarter last year. On average, sell-side analysts forecast that Collegium Pharmaceutical will post 5.62 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Scott Dreyer sold 17,600 shares of the firm’s stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $48.17, for a total transaction of $847,792.00. Following the completion of the sale, the executive vice president owned 103,613 shares of the company’s stock, valued at approximately $4,991,038.21. This trade represents a 14.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Rita J. Balice-Gordon sold 3,650 shares of the business’s stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $47.03, for a total value of $171,659.50. Following the completion of the transaction, the director directly owned 52,629 shares in the company, valued at $2,475,141.87. The trade was a 6.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 2.51% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Collegium Pharmaceutical

Several institutional investors have recently bought and sold shares of the business. Rubric Capital Management LP boosted its stake in Collegium Pharmaceutical by 5.3% in the second quarter. Rubric Capital Management LP now owns 3,157,743 shares of the specialty pharmaceutical company’s stock worth $93,374,000 after purchasing an additional 157,743 shares in the last quarter. Vanguard Group Inc. lifted its position in Collegium Pharmaceutical by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 2,256,254 shares of the specialty pharmaceutical company’s stock worth $104,465,000 after buying an additional 29,876 shares in the last quarter. Renaissance Technologies LLC grew its holdings in Collegium Pharmaceutical by 1.1% during the 4th quarter. Renaissance Technologies LLC now owns 1,617,349 shares of the specialty pharmaceutical company’s stock worth $74,883,000 after acquiring an additional 18,160 shares during the last quarter. Janus Henderson Group PLC grew its holdings in Collegium Pharmaceutical by 59.1% during the 4th quarter. Janus Henderson Group PLC now owns 1,448,578 shares of the specialty pharmaceutical company’s stock worth $67,026,000 after acquiring an additional 538,337 shares during the last quarter. Finally, Principal Financial Group Inc. increased its position in Collegium Pharmaceutical by 0.3% in the 4th quarter. Principal Financial Group Inc. now owns 1,313,662 shares of the specialty pharmaceutical company’s stock valued at $60,823,000 after acquiring an additional 3,891 shares in the last quarter.

Key Headlines Impacting Collegium Pharmaceutical

Here are the key news stories impacting Collegium Pharmaceutical this week:

• Positive Sentiment: Company expects strong growth for its lead product Jornay PM (targets ~31% Jornay revenue growth for 2026) and says it is advancing its pain portfolio—this supports longer‑term top‑line momentum. Article Title
• Positive Sentiment: Needham & Company slightly lowered its price target from $56 to $54 but maintained a “buy” rating, signaling analyst confidence that shares retain upside from current levels. Article Title
• Positive Sentiment: Collegium reported record full‑year net revenues of $780.6M (up 24% YoY) and Q4 net revenues of $205.4M (up 13% YoY), demonstrating solid revenue growth even as profit metrics were mixed. Article Title
• Neutral Sentiment: FY2026 revenue guidance was reiterated/updated to roughly $805M–$825M (in line with consensus), which reduces guidance risk but provides limited upside surprise potential. Article Title
• Neutral Sentiment: Collegium announced a partnership with Boston Legacy FC focused on sensory inclusion and ESG initiatives — positive for brand/ESG profile but limited near‑term financial impact. Article Title
• Neutral Sentiment: Several analyst writeups and a multi‑rating deep dive were published (collecting views from five analysts); useful for tracking sentiment but no consensus rating shock reported. Article Title
• Negative Sentiment: Earnings missed consensus: reported EPS was below expectations (reported $2.04 vs. ~$2.20 expected) and Q4 revenue slightly missed estimates—this is the primary driver of the share weakness today. Article Title
• Negative Sentiment: Earnings call / transcripts highlighted the miss and prompted investor questions on cadence and margins—market reaction to the tone of the call amplified selling pressure. Article Title
• Neutral Sentiment: Short‑interest data posted for February appears to contain errors (reported as 0 shares / NaN increase), so there’s no clear signal from short interest trends at this time. (Data likely unreliable.)
• Negative Sentiment: Trading showed elevated volume versus average as investors sold into the earnings print, contributing to the downward price move today.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.